1. Pink Sheet
  2. >>Market Access

Additional Evidence Persuades England To Reimburse Hemophilia Drug Altuvoct

 
• By Neena Brizmohun

The health technology assessment institute, NICE, has reversed its rejection of Sobi’s once-weekly drug for preventing and treating severe hemophilia A, meaning that the treatment has now secured reimbursement in three European countries.

Concept of blood cells count, medicine and healthcare. 3d rendering mock up
Severe hemophilia A is a lifelong inherited condition that can be life-threatening (Shutterstock)
Key Takeaways
  • NICE, the health technology assessment institute for England, has recommended that Sobi’s Altuvoct (efanesoctocog alfa) should be made available via the National Health Service for treating and preventing bleeding episodes in people aged two years and over with severe hemophilia A.
  • The institute previously rejected the product in draft guidance but Sobi and other stakeholders provided additional evidence that addressed the key uncertainties its appraisal committee had identified at its first meeting.
  • Altuvoct will be the second hemophilia A drug available via the NHS that does not have to be administered every few days as is required when using current factor VIII injections.
  • The other drug is Roche’s Hemlibra (emicizumab) for the prophylaxis of hemophilia A, but unlike Altuvoct it cannot be used as an on-demand treatment.

Altuvoct (efanesoctocog alfa), Sobi’s once-weekly injection for hemophilia A, is to be reimbursed in England, after the company and other stakeholders addressed the key uncertainties that had previously led the...

The treatment costs around £510,000 ($643,020) annually at its list price, but Sobi is making it available to the National Health Service with a discount, for preventing and treating bleeding...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Health Technology Assessment

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 
• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England

 
• By Francesca Bruce

BioMarin’s ultra-rare disease drug Brineura has breached cost-effectiveness thresholds for highly specialized treatments in England and looks set to be denied routine funding on the National Health Service.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

More from Geography

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.